Bioxytran, Inc. · OTC:BIXT
Bioxytran — Investor Presentation (August 2025)
57 slides from Bioxytran's investor presentation, Aug 29, 2025
Slide 1: Bioxytran Inc. - Taking Inflammation Out of People's Lives
Bi XyTran Inc. Taking Inflammation Out of People's Lives
Slide 2: Forward Looking Statement
Forward Looking Statement This Descriptive Presentation (the “Presentation") has been prepared by Bioxytran, Inc (the “Company”) and recipients are not entitled to rely on the accuracy or completeness of the Presentation. Statistical information contained in this Presentation is based on information
Slide 3: Investing Thesis
Investing Thesis • $BIXT has game changing platform technologies • Clinical trial results validated the science (high probability of success) • Has the IP, proprietary science for neutralizing viruses and chronic diseases (Making the World a Better Place) • Extremely compressed valuation – Ideal buy
Slide 4: Drugs made from Complex Carbohydrates
Carbohydrate drugs recognize specific GALECTIN Receptors Drugs The other carbohydrate polymer made from acts as a delivery medium to carry oxygen on HEME Complex Carbohydrates to treat Viral Infections Cancer Oxygen Transport Copyright © Bioxytran 2025. All rights. 4
Slide 5: What are Galectins?
What are GALECTINS? GALECTINS ARE PROTEINS WITH RECEPTORS THAT RECOGNIZE SUGAR MOLECULES AND ARE RESPONSIBLE FOR CHRONIC DISEASES Copyright © Bioxytran 2025. All rights. Version 2.20 5
Slide 6: Galectins Explained
Expertise in Galectin Science to Tackle All Types of Inflammation Galectins Explained A Galectin is a protein that recognizes carbohydrates and modulates intracellular and extracellular interactions primarily related to the immune system. In some cases, Galectins act as a glue bringing surface recep
Slide 7: Galectin-3: One Receptor for an Alphabet of Diseases (A-N)
Galectin-3: One Receptor for an Alphabet of Diseases from A to Z Conditions and diseases in which a role for Gal-3 has been postulated Aa Asthma Bb Blood tests Cc Cancer Dd Degenerative Ee Endometriosis Ff Fibrosis Gg Gastritis Atherosclerosis Cerebral Infarct Aortic stenosis Enteric Nervous System
Slide 8: Galectin-3: One Receptor for an Alphabet of Diseases (O-Z)
Galectin-3: One Receptor for an Alphabet of Diseases from A to Z Conditions and diseases in which a role for Gal-3 has been postulated Oo Obesity Pp Pneumonia Qq Q fever Rr Rheumatoid Ss Sepsis Tt Target therapy Pulmonary HTN Arthritis Systemic Plaque psoriasis sclerosis Uu Vv Ww Xx Yy Yeast infecti
Slide 9: Investment Highlights
Investment Highlights Broad Spectrum Antivirals Cancer Metastasis Blood Substitute Targeting / Fibrosis Carbohydrate chemistry that Designed to deliver Oxygen through neutralizes viruses. Complete Antagonists designed to blood clots in case of stroke, heart reduction of viral load in all patients el
Slide 10: Glycovirology: ProLectin-M
Glycovirology ProLectin-M Copyright © Bioxytran 2025. All rights. Version 2.20 10
Slide 11: Historic Discovery in Virology
Historic Discovery in Virology DISCOVERY Viral adhesion to the cellular membrane is the first step in the process of viral entry and galectins facilitate this process. Both viruses and cells are covered in slippery membranes. Galectins act as the viral glue that can tether the virus to the cell enab
Slide 12: Platform Technology Overview
Platform Technology Overview Broad Spectrum Antiviral Activity Broad Spectrum Antivirals (first case demonstrated in 3 different families ● Carbohydrate chemistry that of viruses) neutralizes viruses via entry ● Galectin-1, 3, 9 are inhibition. Complete reduction modulators of viral infection of vir
Slide 13: Clinical Trial Results Summary
Clinical Trial Results Summary Elimination of the viral load and symptoms within 5 days Reduction of infectivity Quieting the cytokine storm & Reduction of symptoms Robust antibody response (Post-Infection Immunization) 13
Slide 14: ProLectin-M Phase 2 Data: Viral Load (PCR Ct Values)
Prolectin-M Phase 2 Data: Viral Load (PCR Ct Values) Randomized 1:1, double-blind, placebo-controlled trial: ProLectin-M Ct Values Unblinded Data n=34 Treatment of SARS-CoV-2 infection with ProLectin-M Key Outcomes: • Day 3 – 14 out of 17 treated patients were PCR negative (88%) • Day 7 – 17 out of
Slide 15: Elimination of Viral Rebound
Elimination of Viral Rebound There were no rebounds within 14 days. Paxlovid rebound was common after day 10 ¹Galectin approach to lower covid transmission - Drug Development for clinical use (medRxiv.org) https://www.fda.gov/media/155194/download FDA Analysis (Paxlovid Rebound) 15
Slide 16: Improvement in Symptoms
Improvement in Symptoms Frequency of COVID-19 symptoms in the study groups before and after treatment • ProLectin-M treated patients appeared to have relief from symptoms after treatment, compared with placebo • Feeling feverish, body aches/pain, and chills were the most marked improvements measured
Slide 17: Galectin Antagonist Treatment Results in Spike Protein Specific Antibody Immunity
Galectin Antagonist Treatment Results in SARS-CoV-2 Spike Protein Specific Antibody Immunity Introducing Post Infection Immunization Galectin antagonists clear the blood of viral load thereby reducing the strain on the Innate immune system so the Adaptive immune system can build a robust response to
Slide 18: ProLectin-M vs Pfizer's Paxlovid
ProLectin-M vs Pfizer’s Paxlovid Day 3 – 14 out of 17 were PCR negative (88%) Day 20 PCR negative (30%) Day 7 – 17 out of 17 were PCR negative (100%) Toxicity (Drug to Drug Interactions) No toxicity signals Limited to Underlying Medical Conditions. Standard Risk Patients w/o limitations Bioxytran’s
Slide 19: Neutralizing the Spike Protein
Neutralizing the Spike Protein How it Works No Sugar Shield Shielded in Sugar antibody Conserved binding site Common to all variants Galectin Fold Ideal Binding Site Galectin Fold Binding to the spike protein prevents viral entry Antibody Immensely tighter bond to galectin fold vs tip Binding Site (
Slide 20: Galectin Antagonist Tags Virus For Elimination
Galectin Antagonist Tags Virus For Elimination Theoretical Mechanism of Action Virus Galectin Antagonist Liver Filtration Human Cells Approach used for the 1st Time in History of Drug Development Copyright © Bioxytran 2022. All rights. 20
Slide 21: Additional ProLectin-M Indications
Additional ProLectin-M Indications Case Studies on Human Provide Potential Proof of Concept for Follow-On Shingles Case Study Success w/ Galectin Antagonist Herpes Zoster lesions can be painful lasting for days to weeks Topical Galectin Antagonist treatment abated pain in 3 hours Area of lesion Lesi
Slide 22: Additional ProLectin-M Indications: Long COVID
Additional ProLectin-M Indications (Cont) ProLectin-M Theories on Address Long COVID Several Viral Persistence Organ Damage Microclots Autoimmune response Dysbiosis 22
Slide 23: Neutralizing Bird Flu (H5N1) or Influenza (H1N1)
Neutralizing Bird Flu (H5N1) or Influenza (H1N1) Hemagglutinin (HA) spikes involved in viral entry of various Influenza viruses (H1N1, H5N, H3N2, H7N9 Influenza Viruses Alpha Humans, Birds, Mammals Beta Humans, Seals Gamma Humans, Pigs Delta Pigs, Cattle Neutralizing the HA Spike Stops Viral Entry I
Slide 24: Cryogenic Electron Microscopy - Ebola
Cryogenic Electron Microscopy - Ebola ● Mucin-like structures partially cover the Glycan cap which is the site needed for proteolytic cleavage. Removal of mucins may be a perquisite for binding. ● Glycoprotein shedding triggers TLR-4 and proinflammatory cytokines. Strong Potential to Neutralize Ebol
Slide 25: Enormous Markets: No Effective Treatment
Enormous Markets: No Effective Treatment United States Virology Data 2600+ RNA Virus Identified COVID-19 Respiratory Syncytial 103 million Virus (RSV) No Broad-Spectrum solution 2.1 million (toddlers) like Antibiotics (Amoxicillin) for bacterial infections Influenza Viral 26 million Vaccines are una
Slide 26: Cancer Metastasis & Fibrosis: ProLectin-I
CANCER METASTASIS & FIBROSIS ProLectin-I Copyright2025. Copyright © Bioxytran © Bioxytran 2025. All rights. All rights. Version 2.20 2.20 Version 26
Slide 27: Platform Technology Overview
Platform Technology Overview Galectin-3 Target Overcoming Big Pharma’s Checkpoint Inhibitor Resistance Demonstrated Strong Potential Since 2018 Cancer Metastasis Targeting / Fibrosis ● Goal to be first true cancer metastasis trial ● Antagonists designed to ● Galectin-3 antagonists eliminate cancer m
Slide 28: What if Galectins Were Blocked?
High Galectin Expression Leads to Bad Outcomes Study of NSCLC Patients Categorized by Biopsy Galectin Expression Despite all patients testing positive for PD-1 🡪 Galectin-3 expression was extremely accurate in predicting bad outcomes What if Galectins Were Galectin-3 expression on various cancers…
Slide 29: Galectin Effect T-Cell Anergy
Galectin Effect T-Cell Anergy Galectins are responsible for T-Cell Anergy and prevent the LFA-1 lectins TCR Downregulation (depicted in blue) from coalescing at the target cell and developing good adhesion in order to destroy it with cytotoxins. Gal-3 downregulates the number of T- Cell Receptors (T
Slide 30: Reprogramming Tumor, Vasculature, Immune Landscape
Reprogramming Tumor, Vasculature, Immune Landscape Galectins are key modulators of the vasculature, influencing activation, proliferation, and permeability Gal-1 & Gal-3 are common modulators of endothelial cell function during all phases of angiogenesis. In general they are stimulatory, promoting m
Slide 31: One of Cancer's Primary Defense Mechanisms (Gal-3)
One of Cancer’s Primary Defense Mechanisms (Gal-3) Killer T-Cells Must Adequate Adhesion to Kill Impact of Galectin-3 Surrounding Tumor Impact of Gal-3 within the TME. Gal-3 is secreted by the tumor cells as 0 monomers, which can form pentamers and bind substrates. The arrows indicate the influence
Slide 32: Overcoming Immune Checkpoint Resistance
Overcoming Immune Checkpoint Resistance Overexpression of Galectins Drive Several Key Cancer Progression Mechanisms Abstract of our Paper: Immune checkpoint inhibitors (ICIs) have improved therapeutic outcomes in cancer immunotherapy. Despite the advancements, the drawback of primary or acquired res
Slide 33: MOA of Checkpoint Resistance
MOA of Checkpoint Resistance Galectin-3 Occupies the PD-1 Binding Site Galectin-3 has a 3-fold affinity to PD-1 over PD-L1 Surface plasmon resonance shows Gal-3 occupying the receptor site of PD-1. Gal-3 outcompetes PD-L1 binding. Rising Gal-3 levels neg correlated to Response rates and https://www.
Slide 34: Reversing Checkpoint Resistance
Reversing Checkpoint Resistance Galectin-3 Blockers Could End Resistance Low Galectin Staining Predicts Better Outcomes Patients with low Galectin-3 staining on tumors had a 45% ● ICI’s cannot bind to PD-1 due to Galectin-3. chance of survival vs 20% with high Galectin-3 staining ● Blocking Galectin
Slide 35: ProLectin-I: Galectin-3 Inhibitor
ProLectin-I: Galectin-3 Inhibitor Theory: Successful Immunotherapy Requires an Unimpaired Immune System Galectin-3 interferes with immune system function. It favors cancer on multiple pathways that include angiogenesis, metastasis, and a suppressive tumor microenvironment. It also negatively interfe
Slide 36: Galectin Trouble-Maker
Galectin Trouble-Maker The Center of Inflammatory Feedback Loops Gal-3 is a Pro-inflammatory Molecule Inhibiting it blocks cycle of inflammation Galectin is the KEY modulator of inflammatory molecules http://jpet.aspetjournals.org/content/351/2/336 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC575217
Slide 37: Galectins Impair the Immune System
Galectins Impair the Immune System Example Survival Curve Categorized by Galectin Expression When Galectin-1 starts to elevate it impairs the cancer patient's immune system. Cancer patients with less impairment have a better chance of survival. Low Stromal Gal-1 Expression is Associated with Long Te
Slide 38: Clinical Evidence Summary
Clinical Evidence Summary Two clinical trials have shown augmentation of ICI therapy with Galectin-3 inhibitors Potential reduction in immune- related side effect profile Observed clinical effect likely due to multiple mechanisms of action Galectin-3 expression correlates with ICI non-response 38
Slide 39: Clinical Evidence: Cancer Trial Results - Gal-3 Antagonists
Clinical Evidence: Cancer Trial Results – Gal-3 Antagonists Belapectin in Cohort 2 had a 100% ORR in advanced Melanoma for an 85-day trial using PET Scan Before and optimal dosage. After of Melanoma patient is the Complete 1 in 5 had a Complete Response Response in Cohort 2 (All Tumors Resolved) 50%
Slide 40: Clinical Evidence: Cancer Trial Results - Gal-3 Antagonists
Clinical Evidence: Cancer Trial Results – Gal-3 Antagonists GB1211 in NSCLC w/Atezolizumab (ATZ) 4/10 (40%) achieved a Partial Response Cohort1 (100 mg) 3/5 (60%) achieved a Partial Response Cohort2 (200 mg) Gal-3 Serum levels decreased in responders Gal-3 Serum levels decreased in Atezolizumab ORR
Slide 41: Checkpoint Inhibitor Landscape: Ideal Partners
Checkpoint Inhibitor Landscape: Ideal Partners Drug Name Company Target Ipilimumab (Yervoy) Bristol-Myers Squibb CTLA-4 Nivolumab (Opdivo) Bristol-Myers Squibb PD-1 Relatlimab (Opdualag) Bristol-Myers Squibb LAG-3 Pembrolizumab (Keytruda) Merck PD-1 Atezolizumab (Tecentriq) Genentech/Roche PD-L1 Dur
Slide 42: ProLectin-I
ProLectin-I Galectin-3 drives many pathophysiological ProLectin-I Preclinical Data: process in fibrotic diseases and cancer • Pre-clinical studies in Mice and Rats show no toxicity and high tolerance. • IND Approved in India for a toxicity study in 30 healthy human subjects. • Intravenous Galectin-3
Slide 43: Blood Substitute: Universal Oxygen Carrier (UOC)
BLOOD SUBSTITUTE Universal Oxygen Carrier (UOC) Copyright © Bioxytran 2025. All rights. Version 2.20 43
Slide 44: Platform Technology Overview
Platform Technology Overview Proof of Concept in Animals Continuing Blood Substitute (2 of 4 Animal Species completed testing) ● Designed to deliver Oxygen through blood clots in case of stroke, heart attack, or Sickle Cell Anemia. ● No Side Effects ● Increase cerebral oxygenation for ● No change in
Slide 45: Blood Substitute Universal Oxygen Carrier (UOC)
Blood Substitute Universal Oxygen Carrier (UOC) UOC BXT-25 Oxygen Bridge polymer • UOC is a hemoglobin-based polymer; over 1,000 times smaller than a red blood cell • BXT-25 can be used both in Ischemic and Hemorrhagic Stroke • It can penetrate a blood-clot and reach the brain within 3 minutes • Red
Slide 46: Animal Study Hemorrhagic Model - UOC
Animal Study Hemorrhagic Model- UOC Investigating the dose-dependent effects of UOC, on various physiological parameters in dogs experiencing severe oxygen debt from hemorrhagic shock. 24 dogs were divided into 4 groups, receiving different doses of UOC (0.0, 0.065, 0.325, or 0.65 g/kg) along with s
Slide 47: Animal Study Stroke Model - UOC
Animal Study Stroke Model - UOC Oxygen delivery and brain recovery in Absence of nitric oxide scavenging, no Simulated Oxygenation to the brain with a clot. stroke induced rats with similar increased blood pressure in diabetic mice chemistry to UOC (Harvard Medical (Harvard Medical School, 2013) Sch
Slide 48: Animal Studies - UOC
Animal Studies - UOC Universal Oxygen Carrier (UOC) Rats and Rabbits Observations through 8 days concluded: Four treatment groups in each study: • No changes in PO₂ • No changes in Hb 1. UOC treatment (10% blood volume) • No changes in SO₂ 2. UOC treatment (20% blood volume) • No changes in blood pH
Slide 49: Stroke: The Golden Hour Dilemma
Stroke: The Golden Hour Dilemma Time to Needle 2.5 hours Onset of symptoms Ambulance arrives Arrival and initial Thombolysis or Blockage Removed Equivalent to at home assessment and PTCA/CABG 9 Years of Aging treatment in ER Copyright © Bioxytran 2024. All rights. Version 1.01.01 49
Slide 50: FDA Approved Companion Diagnostics
FDA Approved Companion Diagnostics MDX-Viewer clinical end-point for measuring oxygen delivery to the brain in real-time Flat probe Tissue/brain monitored parameters Treated Mitochondrial NADH (ATP) Brain metabolic score Aneurysm Hb Saturation (O₂) Cerebral Blood Flow 90 Tissue Reflectance Tissue me
Slide 51: Development Pipeline
Development Pipeline Completed Planned Product Indication Preclinical IND Submission Phase I Phase II Phase III Phase IV Virology – Mild to Moderate ProLectin-M • Covid-19 Oral • Influenza • Other virologic diseases Virology – Severe cases ProLectin-I • Covid-19, Long Covid Intravenous • Other virol
Slide 52: Competitive Landscape
Competitive Landscape Company Area of Indication Gal-3 Inhibitors Drug Name Phase Interest Therapeutic Class Galectin Hepatology MASH Cirrhosis Complex Polysaccharide Belapectin 2b/3 Therapeutics (GR-MD-02) Galecto Biotech Oncology NSCLC, HNSCC, MM Small Molecule GB1211 2 TrueBinding Neurology Alzhe
Slide 53: Bioxytran Inc. (Biological Oxygen Transfer)
Inc (Biological Oxygen Transfer) Location: Boston, MA Symbol: BIXT (OTCQB) Formation: 2017 SEC Fully Reporting Public Company Funding: Accredited Investors (Audited) No Venture Capital Money • 2000 Shareholders Licensing Strategy – Big Pharma to • 88M Shares Outstanding commercialize it • 50%+ Insid
Slide 54: IP Portfolio
IP Portfolio Intellectual Property (IP) • Three (3) issued worldwide patents • One (1) issued US patent • One (1) provisional worldwide patent • Additional applications to strengthen our IP position are ongoing* * Future patents to be filed at commercialization stage 1. Pharmalectin has received an
Slide 55: Key Leadership in Galectin Science
Key Leadership in Galectin Science David Platt PhD, CEO, CSO, Chairman Galectin Science Leader Resulted in First Article in field of research - 1993 10,000+ 40+ years Journal Articles on of research in Galectins, Target Receptors carbohydrate-binding proteins • 2 Textbooks • 5 Public Companies (IGGI
Slide 56: Experienced Management Team, Cost Efficient Development, De-Risked Science
Experienced Management Team Cost Efficient Development De Risked Science Funds spent on advancing clinical trial Efficacy proven in peer-reviewed journals. Demonstrated ability to navigate regulatory development not R&D Viral Elimination. Regulatory approval to climate in record time & multiple juri
Slide 57: BioXyTran, Inc.
BioXyTran, Inc. 75 Second Avenue Needham MA, 02494 (617)-454-1199 www.bioxytraninc.com Copyright © Bioxytran 2025. 2024. All rights. Version 1.01.01